SUBSCRIBE
SUBSCRIBE
Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than five years experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 200 features and breaking news articles with a particular focus in neuroscience and gene therapy. She has also traveled internationally to cover global biotech hubs such as Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Business
Aerosol Scientist: Masks, Saline Cleansers May Have Enduring Value Beyond COVID-19
With COVID-19 ducking for cover and going into an almost full retreat across the U.S., Americans are throwing caution – and masks – to the wind. But many are still nervous, and wondering: How do we protect ourselves in this brave new normal?
June 24, 2021
 · 
4 min read
 · 
Heather McKenzie
Bio NC
BioSpace Publishes 2021 U.S. Life Sciences Salary Report, Examines Salary Growth Despite Challenges
As BioSpace releases its third annual 2021 U.S. Life Sciences Salary Report, there are hopeful surprises and unsettling truths.
June 23, 2021
 · 
4 min read
 · 
Heather McKenzie
Drug Development
Inside ReCode’s New-in-Class Approach to Treating Cystic Fibrosis
The data showed that both experimental therapies restored function in the cystic fibrosis transmembrane conductance regulator gene.
June 17, 2021
 · 
5 min read
 · 
Heather McKenzie
Drug Development
Xilio Rides First Half Momentum to IND Acceptance for Checkpoint Inhibitor
XTX101 is a tumor-selective anti-CTLA-4 monoclonal antibody designed to improve upon the safety of current therapies in the same class.
June 17, 2021
 · 
2 min read
 · 
Heather McKenzie
Drug Development
ENA Respiratory Raises AU$32 Million for Preventative Nasal Spray Against COVID-19
The company’s lead candidate, INNA-051, is an innate immune agonist that directly stimulates the host’s natural immune defense system.
June 16, 2021
 · 
3 min read
 · 
Heather McKenzie
Business
Mnemo Breaks French Series A Record, Targets Greater Tumor Specificity
The Paris-based biotech will use the funds to create targeted immuno-oncology treatments for a broader range of patients with its next-generation CAR-T and epigenetics platform.
June 15, 2021
 · 
3 min read
 · 
Heather McKenzie
Policy
Discovery of New Childhood Form of ALS Could Inform Future Research
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
June 15, 2021
 · 
5 min read
 · 
Heather McKenzie
Photo courtesy of Capsida Biotherapeutics Inc.
Business
CRISPR and Capsida Partner in Gene Edited Therapies for ALS, Friedreich’s Ataxia
Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.
June 14, 2021
 · 
3 min read
 · 
Heather McKenzie
Drug Development
Are Vindictive Variants Threatening Our COVID-19 Recovery?
According to the CDC, the Delta variant now accounts for more than 6% of infections in the U.S. and may be responsible for 18% of cases in some Western states.
June 10, 2021
 · 
5 min read
 · 
Heather McKenzie
Policy
Aduhelm Approval Draws Mixed Reaction, Sparks New Controversy Over Pricing
Not everyone is so confident that Aduhelm will transform the Alzheimer’s drug development landscape.
June 8, 2021
 · 
5 min read
 · 
Heather McKenzie
Nathan Stirk/Getty Images
Drug Development
AstraZeneca Redefining Cancer Care in Breast Cancer, Leukemia at ASCO
After three years, 85.9% of patients treated post-surgically with Lynparza were free of invasive breast cancer and second cancers compared to 77.1% of the placebo group.
June 7, 2021
 · 
3 min read
 · 
Heather McKenzie
Genetown
Cellarity: Transforming Drug Development at the Confluence of Biology and Machine Learning
In the field of drug discovery, one must always begin with the target, right? Not if you ask Cellarity, a quickly emerging biotech company revolutionizing the drug development space.
June 4, 2021
 · 
5 min read
 · 
Heather McKenzie
Drug Development
Novartis Breaks Through with Radioligand Therapy for Prostate Cancer
Today, the Swiss pharma titan announced the results of its Phase III VISION study, where 177Lu-PSMA-617 plus best standard of care (SOC) met both of its primary endpoints.
June 3, 2021
 · 
4 min read
 · 
Heather McKenzie
Business
Experts: Previous COVID-19 Infection Not a ‘Get Out Of Jail Free’ Card
Importantly, the researchers recovered virus that they were able to culture, indicating a high risk for transmissibility.
June 3, 2021
 · 
4 min read
 · 
Heather McKenzie
Drug Development
Calliditas is Getting to the Heart of Berger’s Disease
Calliditas is developing Nefecon, a down regulator of IgA1 and proprietary, novel oral formulation of budesonide – a potent and established immunosuppressant – for the treatment of IgAN.
June 2, 2021
 · 
4 min read
 · 
Heather McKenzie
Load More